Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Li

Showing results (161-170 of 206) with videos related to

Pageof 21
Sort By:
Journal for Immunotherapy of Cancer|March 18, 2025
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)Gliceida M Galarza Fortuna, Daniel Grass, Benjamin L Maughan, et al.
European Urology|June 26, 2026
Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management ImplicationsCan Aydogdu, Laura Bukavina, Liang Cheng, et al.
Urologic Oncology|October 25, 2023
Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancerRoger Li, Shreyas Naidu, Wenyi Fan, et al.
Urologic Oncology|May 21, 2020
Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) membersJustin T Matulay, William Tabayoyong, Jonathan J Duplisea, et al.
European Urology Oncology|July 27, 2025
FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial CarcinomaRenate Pichler, Nils C H van Creij, Laura S Mertens, et al.
Targeted Oncology|April 3, 2024
Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder CancerJacob B Leary, Thomas Enright, Dimitra Rafailia Bakaloudi, et al.
BJU International|September 11, 2025
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomyAdnan Fazili, Seyed Behzad Jazayeri, Kyle M Rose, et al.
Clinical Genitourinary Cancer|July 20, 2024
Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder CancerWilliam Paul Skelton, Jack Masur, Jonathan Thomas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 14, 2024
Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2Jessica M Posada, Evgeny Yakirevich, Ashish M Kamat, et al.
The Journal of Urology|November 13, 2025
Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-preserving Trimodality TherapyDekuang Zhao, Vaseem M Khatri, Justyn Y Nakashima, et al.
Pageof 21

Showing results (161-170 of 206) with videos related to

Sort By:
Pageof 21
Journal for Immunotherapy of Cancer|March 18, 2025
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)Gliceida M Galarza Fortuna, Daniel Grass, Benjamin L Maughan, et al.
European Urology|June 26, 2026
Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management ImplicationsCan Aydogdu, Laura Bukavina, Liang Cheng, et al.
Urologic Oncology|October 25, 2023
Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancerRoger Li, Shreyas Naidu, Wenyi Fan, et al.
Urologic Oncology|May 21, 2020
Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) membersJustin T Matulay, William Tabayoyong, Jonathan J Duplisea, et al.
European Urology Oncology|July 27, 2025
FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial CarcinomaRenate Pichler, Nils C H van Creij, Laura S Mertens, et al.
Targeted Oncology|April 3, 2024
Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder CancerJacob B Leary, Thomas Enright, Dimitra Rafailia Bakaloudi, et al.
BJU International|September 11, 2025
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomyAdnan Fazili, Seyed Behzad Jazayeri, Kyle M Rose, et al.
Clinical Genitourinary Cancer|July 20, 2024
Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder CancerWilliam Paul Skelton, Jack Masur, Jonathan Thomas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 14, 2024
Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2Jessica M Posada, Evgeny Yakirevich, Ashish M Kamat, et al.
The Journal of Urology|November 13, 2025
Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-preserving Trimodality TherapyDekuang Zhao, Vaseem M Khatri, Justyn Y Nakashima, et al.
Pageof 21